339 related articles for article (PubMed ID: 16776856)
1. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
2. Origins and molecular pathology of ovarian cancer.
Bell DA
Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
4. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
5. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
6. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
8. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
10. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
Kurman RJ; Shih IeM
Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
[TBL] [Abstract][Full Text] [Related]
12. Precursors and pathogenesis of ovarian carcinoma.
Lim D; Oliva E
Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
[TBL] [Abstract][Full Text] [Related]
13. [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].
Staebler A; Diebold J
Pathologe; 2007 May; 28(3):180-6. PubMed ID: 17431628
[TBL] [Abstract][Full Text] [Related]
14. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
15. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
16. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
17. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
Oliva E; Sarrió D; Brachtel EF; Sánchez-Estévez C; Soslow RA; Moreno-Bueno G; Palacios J
J Pathol; 2006 Apr; 208(5):708-13. PubMed ID: 16429393
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 Oct; 39(10):1010428317733984. PubMed ID: 28992761
[TBL] [Abstract][Full Text] [Related]
19. Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation.
Kim KR; Choi J; Hwang JE; Baik YA; Shim JY; Kim YM; Robboy SJ
Histopathology; 2010 Oct; 57(4):587-96. PubMed ID: 20955384
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis.
Stewart CJ; Leung Y; Walsh MD; Walters RJ; Young JP; Buchanan DD
Hum Pathol; 2012 Aug; 43(8):1177-83. PubMed ID: 22305241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]